HK-10、IGF-Ⅰ和SMRP在卵巢癌患者中的表达及意义

目的 观察人激肽释放酶-10(human kallikrein-10, HK-10)、胰岛素样生长因子-I(insulin-like growth factor-I,IGF-Ⅰ)和可溶性间皮素相关蛋白(soluble mesothelin-related proteins, SMRP)在卵巢癌患者中的表达及意义。方法 选择卵巢癌患者76例为卵巢癌组,同期行手术治疗卵巢良性肿瘤患者30例为卵巢良性肿瘤组,健康体检者20例健康对照组。采用ELISA法检测各组血清HK-10、IGF-Ⅰ和SMRP水平,比较卵巢癌组术前和术后,卵巢良性肿瘤组和健康对照组的血清HK-10、IGF-Ⅰ和SMRP水平；分析卵巢癌患者血清HK-10、IGF-Ⅰ和SMRP水平与临床病理指标之间的关系。结果 3组患者血清HK-10、IGF-Ⅰ和SMRP水平差异有统计学意义(F=56.157,P<0.01；F=280.021,P<0.01； F=819.326,P<0.01)。术前,卵巢癌组血清HK-10和SMRP水平较卵巢良性肿瘤组(t1=7.054,t2=27.939,P<0.01)和健康对照组(t1=6.514,t2=22.755,P<0.01)明显升高；术后,卵巢癌组血清HK-10(t=11.434,P<0.01)和SMRP(t=43.760,P<0.01)较术前明显降低,而卵巢良性肿瘤和健康对照组差异无统计学意义(P>0.05)。卵巢癌患者术前血清IGF-Ⅰ水平较卵巢良性肿瘤组(t=13.580,P<0.01)和健康对照组(t=18.592,P<0.01)明显降低,术后卵巢癌患者血清IGF-Ⅰ水平较术前明显升高(t=15.955,P<0.01),而卵巢良性肿瘤组血清IGF-Ⅰ水平明显高于健康对照组(P<0.01)。卵巢癌患者血清HK-10和SMRP水平随着肿瘤分化程度升高而降低,而IGF-Ⅰ相反(P<0.01)；血清HK-10和SMRP水平随着肿瘤直径、CA125数值增大,转移程度、肿瘤分期升高而升高,而IGF-Ⅰ相反(P<0.01)；血清HK-10、IGF-Ⅰ和SMRP水平不随患者年龄和病理类型改变而改变(P>0.05)。卵巢癌患者血清IGF-Ⅰ水平与HK-10(r=-0.628,P<0.05)和SMRP(r=-0.738,P<0.05)水平呈负相关,而HK-10与SMRP水平呈正相关(r=0.582,P<0.05)。结论HK-10、IGF-Ⅰ和SMRP参与了卵巢癌的发生发展过程,对于卵巢癌的诊断和预后具有重要临床价值。
Objective To investigate the serum levels of human kallikrein 10 (HK-10), insulin-like growth factor-Ⅰ(IGF-Ⅰ) and soluble mesothelin-related proteins (SMRP) in patients with ovarian cancer. Methods Seventy six patients with ovarian cancer, 30 patients with benign ovarian disease and 20 healthy women were enrolled in the study. Serum HK-10, IGF-Ⅰ and SMRP levels were measured by ELISA. The HK-10, IGF-Ⅰ and SMRP levels were compared among patients with ovarian cancer, benign ovarian disease and normal controls. The correlation of serum HK-10, IGF-Ⅰ and SMRP with clinicopathological features of ovarian cancer patients was analyzed. Results There were significant differences in serum levels of HK-10, IGF-Ⅰ and SMRP among three groups (F=56.157, P<0.01; F=280.021,P<0.01; F=819.326, P<0.01). Serum HK-10 and SMRP levels in ovarian cancer patients were significantly higher than those in ovarian benign disease (t1=7.054, t2=27.939, P<0.01) and healthy controls (t1=6.514, t2=22.755, P<0.01). The IGF-Ⅰ levels in ovarian cancer patients were significantly lower than those in ovarian benign tumor group (t=13.580, P<0.01) and healthy control group (t =18.592, P<0.01). The levels of HK-10 (t=11.434, P<0.01) and SMRP (t=43.760, P<0.01) in ovarian cancer group after surgery were significantly lower than those before surgery; and there were no significant differences in HK-10 and SMRP between benign ovarian tumor group and healthy